U.S. health officials have paused the distribution of two Eli Lilly & Co. Covid-19 monoclonal antibody treatments because of data showing they aren’t effective against virus variants that are becoming increasingly common across the country.
U.S. health officials have paused the distribution of two Eli Lilly & Co. Covid-19 monoclonal antibody treatments because of data showing they aren’t effective against virus variants that are becoming increasingly common across the country.